Sandbox gc3: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
mNo edit summary
Line 27: Line 27:
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 7/384 (2%)
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 7/384 (2%)
|-
|-
 
| rowspan=2 style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Total Bilirubin Increased
 
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Grade 3
 
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 1/193 (1%)
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 3/190 (2%)
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 4/383 (1%)
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Grade 4
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 0
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 1/190 (1%)
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 1/383 (<1%)
|-
|}
|}

Revision as of 21:08, 2 July 2020

Hepatic Laboratory Abnormalities—Study GS-US-540-5773 Remdesivir for 5 Days Remdesivir for 10 Days Total
ALT Increased Grade 3 8/194 (4%) 11/191 (6%) 19/385 (5%)
Grade 4 4/194 (2%) 5/191 (3%) 9/385 (2%)
AST Increased Grade 3 11/194 (6%) 7/190 (4%) 18/384 (5%)
Grade 4 3/194 (2%) 4/190 (2%) 7/384 (2%)
Total Bilirubin Increased Grade 3 1/193 (1%) 3/190 (2%) 4/383 (1%)
Grade 4 0 1/190 (1%) 1/383 (<1%)